Results 111 to 120 of about 6,478 (160)

Economic Evaluation of Oral Nirmatrelvir-Ritonavir for COVID-19 in Higher Risk Outpatients.

JAMA Netw Open
Png ME, Harris V, Yu LM, Little P, Hobbs FDR, Butler CC, Petrou S, PANORAMIC Trial Collaborative Group.   +7 more
europepmc   +1 more source

Design, synthesis, and X-ray structural studies of potent SARS-CoV-2 Mpro inhibitors containing tetrahydroisoquinoline-3-carboxamides as P2 ligands. [PDF]

RSC Med Chem
Ghosh AK, Sharma A, Iddum S, Bogan SN, Jayashankar U, Lendy EK, Hattori SI, Higashi-Kuwata N, Mitsuya H, Mesecar AD.   +9 more
europepmc   +1 more source

International Collaboration to Develop and Harmonize Drug Interaction Guidance for Nirmatrelvir/Ritonavir During COVID-19: Lessons Learned for Future Pandemic Preparedness. [PDF]

Clin Infect Dis
Kuriakose S, Tseng A, Boyd S, Gibbons S, Chiong J, Marra F, Boyle A, Senneker T, George J, Lund C, Belperio P, Crew P, Eschenauer G, Scarsi KK, Khoo SH, Pau A, Marzolini C, LiON-PK collaboration.   +17 more
europepmc   +1 more source

Slowly exchanging bound states of SARS-CoV-2 3CL^pro-inhibitor complexes revealed by ¹⁹F NMR. [PDF]

Struct Dyn
De Falco A, Shurina B, Greene-Cramer R, Ramelot TA, Montelione GT.   +4 more
europepmc   +1 more source

Effectiveness of nirmatrelvir/ritonavir and molnupiravir on post-COVID diabetes risk among an older adult cohort: a target trial emulation study. [PDF]

BMC Med
Guo Z, Wei Y, Yang A, Wong CKH, Xiong X, Wang K, Lin G, Wang H, Hung CT, Li C, Yam CHK, Chow TY, Zhao S, Mok CKP, Hui DSC, Yeoh EK, Chong KC.   +16 more
europepmc   +1 more source

Managing High-Risk Drug Interactions With Nirmatrelvir/Ritonavir: Experience From a Dedicated Pharmacology Advice Service. [PDF]

Clin Transl Sci
Libiad Y, Franck B, Tron C, Lalanne S, Boglione-Kerrien C, Taïeb F, Verdier MC, Lemaitre F.   +7 more
europepmc   +1 more source

Antivirals Targeting Coronavirus RNA-Dependent RNA Polymerase and Main Protease: From Mechanisms of Action to Outcomes in COVID-19 Clinical Trials. [PDF]

Microb Biotechnol
Brüssow H.
europepmc   +1 more source

Characteristics of outpatient nirmatrelvir/ritonavir recipients during the 2022/2023 era in Alberta, Canada: A retrospective observational population-based study. [PDF]

Can Commun Dis Rep
Vu K, Randall J, Martins K, Aponte-Hao S, Saxinger L, Leal J, Rennert-May E, Rafferty E, Nguyen PU, Williamson T, Klarenbach S.   +10 more
europepmc   +1 more source

Clarifications in JAMA Clinical Guidelines Synopsis.

JAMA
europepmc   +1 more source